Incyton

Executive Summary

Incyton is a German biotechnology company founded in 2018 that has developed CYRIS, an AI-powered, label-free multisensor platform for real-time, multiparametric cell analysis. The platform enables simultaneous monitoring of key cellular parameters, offering significant advantages over traditional endpoint assays in drug discovery and academic research. By providing automated assay platforms, consumables, and tailored assay development services, Incyton addresses the growing demand for high-content, label-free technologies that can accelerate lead identification and toxicity screening. The company is privately held, based in Dresden, and has not disclosed funding rounds or revenue, suggesting it is still in early commercialization or growth stage. Its technology has potential relevance across oncology, immunology, and neuroscience applications.

Upcoming Catalysts (preview)

• TBDPharmaceutical Partnership or Licensing Deal60% success
• TBDSeries A Funding Announcement70% success
• TBDLaunch of Next-Generation CYRIS Platform50% success